Information de reference pour ce titreAccession Number: | 00029330-200607010-00001.
|
Author: | LI, Jian-jun; XU, Bo; YANG, Yue-jin; MA, Wei-hua; CHEN, Ji-lin; QIAO, Shu-bing; QIN, Xue-wen; YAO, Min; LIU, Hai-bo; WU, Yong-jian; YUAN, Jin-qing; CHEN, Jue; YOU, Shi-jie; DAI, Jun; XIA, Ran; GAO, Run-lin
|
Title: | A comparison of angiographic and clinical outcomes after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis.[Article]
|
Source: | Chinese Medical Journal (English Edition). 119(13):1059-1064, July 2006.
|
Abstract: | Background: In-stent restenosis (ISR) remains a challenge for interventional cardiologists. Some data suggest that drug-eluting stents (DES) represent a promising new option for the treatment of patients with ISR. Currently, 2 DES platforms are available [sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) ], but the superiority of either approach for treating ISR has not been convincingly demonstrated. The aim of the present study was to retrospectively compare angiographic and clinical outcomes after treatment of ISR with SES or PES in a series of consecutive patients with ISR.
Methods: A total of 745 consecutive patients were treated with bare metal stents from April 12, 2004 to December 31, 2004 in our center. Of these, clinically driven target lesion revascularization (TLR) was performed in 54 ISR from 54 patients at 7 months. Of the 54 patients with ISR, 36 received SES and 18 received PES. Follow-up included angiography and assessment of clinical outcome, both performed 7 months after DES implantation.
Results: There were no significant differences in baseline clinical data (including medication usage and lesion characteristics) between the two groups. Except for overlapping of multiple stents, procedural parameters were also similar in both groups. Seven-month angiographic follow-up showed that the binary restenosis rate was higher in patients treated with PES than that in patients treated with SES (in-stent binary restenosis: 27.8% vs 5.6%, P<0.023; In-segment binary restenosis: 44.4% vs 13.9%, P<0.014). Major adverse cardiac events (MACE) occuring during hospitalization or during the follow-up period including thrombosis and TLR was similar in both groups (22.2% vs 8.3%, P>0.05).
Conclusions: Results from this small sample size, retrospective, single-center study showed that SES might be superior to PES in treating ISR because of lower 7-month restenosis rates (both in-stent and in-segment binary restenosis) with no increased incidence of MACE.
(C) 2006 Chinese Medical Association
|
Author Keywords: | coronary artery disease; drug-eluting stent; restenosis; angiography.
|
References: | 1. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, Lopez-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003;42:796-805.
2. Bauters C, Banos JL, Van Belle E, Mc Fadden EP, Lablanche JM, Bertrand ME, et al. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation 1998;97:318-321.
3. Mahdi NA, Pathan AZ, Harrell L, Leon MN, Lopez J, Butte A, et al. Directional coronary atherectomy for the treatment of Palmaz-Schatz in-stent restenosis. Am J cardiol 1998;82:1345-1351.
4. Mehran R, Dangas G, Mintz GS, White RL, Chan RC, Gierlach LM, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation 2000;101:2484-2489.
5. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-1878.
6. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193.
7. Sousa JE, Costa MA, Abizaid A, Sousa AGMR, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-27.
8. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
9. Degertekin M, Regar E, Tanabe K, Smits P, van der Giessen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. J Am Coll Cardiol 2003;41:184-189.
10. Commeau P, Barragan PT, Roquebert PO, Simeoni JB. ISR II study: a long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions. Catheter Cardiovasc Inter 2005;66:158-162.
11. Rahe B, Suttorp MJ, Te Riele HA, Bal ET, Ernst SM, Mast EG, et al. Stenting for restenotic lesions with the BARD XT stent. J Interven Cardiol 2003;16:227-230.
12. Schiele TM, Konig AK, Rieber J, Erhard I, Leibig M, Theisen K, et al. Sirolimus-eluting stent implantation and (-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. Am Heart J 2005;150:351-357.
13. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trail. JAMA 2005;293:165-171.
14. Neumann FJ, Desmet W, Grube E, Brachmann J, Presbitero P, Rubartelli P, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005;111:2107-2111.
15. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004;25:902-919.
16. Colombo A. The 0% restenosis study. Ital Heart J 2002;3:559-561.
17. Xu B, Li JJ, Yang YJ, Ma WH, Chen JL, Qiao SB, et al. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients. Chin Med J 2006; 119: 533-538.
18. Colombo A, Lakovou I. Drug-eluting stents: the new gold standard for percutaneous coronary revascularization. Eur Heart J 2004;25:895-897.
19. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. J Am Coll Cardiol 2005;45:308-311.
20. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg ML. A hierachical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004;364:583-591.
|
Language: | English.
|
Document Type: | Original article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0366-6999
|
Annotation(s) | |
|
|